Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals

Sep. 16, 2022 12:41 PM ETPfizer Inc. (PFE)

Summary

  • After a slow first half, merger and acquisition deals are heating up for the remainder of 2022.
  • In the efforts to boost its presence in rare hematology, Pfizer recently announced it is acquiring Global Blood Therapeutics for $5.4B.
  • Global Blood Therapeutics has several intriguing molecules that could garner blockbuster sales for Pfizer in the coming years.
  • Looking for higher risk/reward options trading ideas? I offer this and much more at my exclusive investing ideas service, Integrated BioSci Investing. Learn More »

Blood cells

Pixelimage

logo

GBT

Price is what you pay. Value is what you get. - Warren Buffett

When you invest in biotech, it's exciting to see your company getting acquired. After all, the acquisition price is usually at a premium to the market valuation. That being said, there were a good number of stocks that I have covered over the years that got bought out. Don't nail me at the stake here. I'm not bragging. Instead, I want to show you that investing in high-quality fundamental stocks usually rewards you via either a merger and acquisition (i.e., M/A) or an organic share price appreciation in the long run.

In this article, I'll feature a fundamental analysis on the recent Global Blood Therapeutics, Inc. (GBT) acquisition by Pfizer (NYSE:PFE). I hope that you'll pick out nuggets in this article to assist you in forecasting other upcoming deals.

Figure 1: GBT chart

GBT chart

StockCharts

About The Company

As usual, I'll deliver a brief corporate overview for new investors. If you are familiar with the firm, I suggest that you skip to the subsequent section. I noted in the prior article:

Operating out of San Francisco, California, GBT is focused on the development and commercialization of novel medicines to serve the unmet needs of the debilitating blood disorder coined sickle cell disease ("SCD"). Notably, GBT already launched Oxbryta in the U.S. for adults and kids (age 4-11) suffering from SCD. In February 2022, GBT also received Oxbryta's marketing authorization in the European Union (i.e., EU) for kids in the same age group.

Figure 2: Therapeutic pipeline

pipeline

GBT

Tracking GBT Investment Thesis

As you know, it's important to place your stocks into their appropriate investment categories. That way, you can better track their development and progress. On this note, I classified GBT as a "growth biotech" that is still in its aggressive growth phase. As the crown jewel of the pipeline, Oxbryta was launched in the past few years. Being a prudent growth company, GBT continues to expand Oxbryta's label as well as penetrating into additional markets. Of note, the most recent advancement is the label expansion to serve kids.

To track GBT's growth story, you want to follow the sales growth to see if the company can continue to ramp up Oxbryta sales. That aside, you want to follow on other pipeline drugs (i.e., inclacumab and GBT601) to ascertain that they are catered for related conditions, i.e., blood disorders. Here, you should look for additional regulatory approvals and more market penetration for those assets. So long as that story remains the same, you can hold GBT indefinitely for multiple-fold gains. The other "exit situation" is when the company can get bought out. As you know, that is the main focus on this article.

Mergers & Acquisition

On August 08, Pfizer announced that the company would acquire GBT for $5.4B (i.e. at $68.50 per share). The move is to enhance Pfizer's presence in rare hematology. That is to say, Pfizer is poised to strengthen its rare blood diseases portfolio. Accordingly, Pfizer estimated that GBT's portfolio along with other pipeline assets would garner another $3B in annual sales. As Pfizer is a global powerhouse with its vast sales/marketing team, you can project that the firm would fully unlock the value of GBT's drugs.

Metric #1: Favorable M/A Environment

Now, let us analyze the factors conducive to this acquisition. That way, we can employ similar metrics to size up other potential buyouts. The first criteria that I look at is a favorable market environment. As you can see, the biotech market (and the stock market in general) have been in steep decline for the past two years.

Keep in mind that despite the recent biotech resurgence, many bio-equities are still trading at a deep bargain to their intrinsic value. The fact that many potential acquisition targets are trading far below their true worth should entice more acquisitions. If you put yourself in the shoes of the acquirer, would you prefer to pick up the same company at a steep discount? I know I would.

Viewing the current M/A environment, you are likely to see more deals going toward yearend as well as next year. As you can see, my sentiment resonates with the Big Four accounting firm (i.e., PwC). Specifically, PwC stated that M/A biotech deals are expected to pick up robustly in 2H2022. According to a PwC research report,

All of the stars are aligned for there to be a flurry of deals activity across all areas of the sector despite the slow start to the year so far. Many large pharma players are flush with cash (particularly those that have COVID-19 treatments in their arsenal), biotech valuations have been normalizing after years of a boom market and the 2025 patent cliff is rapidly approaching, all making for a strong deal environment.

Figure 3: Notable 2022 biotech deals

notable biotech deals

PwC

Metric #2: Premium Acquisition Price

Asides from the acquirer (i.e., Pfizer), you have to view the aforesaid deal in the eyes of the buyout target (i.e., GBT). For the Board of Directors to agree to sell the company, they demand a premium price. At $5.4B (i.e., at $68.50 per share), Pfizer bought GBT at over 40% premium to the stock's pre-deal valuation.

Figure 4: Premium acquisition price

GBT premium acquisition price

Seeking Alpha

As you can imagine, it makes sense for GBT to request for a premium acquisition valuation. After all, the Board and shareholders won't approve the deal if the price is not right. As you recall, Pfizer estimated that the GBT should deliver roughly $3B in annual sales.

If you put $3B in sales against the $5.4B in buyout price, you're looking at the projected price/sales ratio of 1.8. At that valuation metric, Pfizer is getting a great deal. Nevertheless, I believe that the +40% premium and the ability of Pfizer to fully unlock the value of Oxbryta/other GBT's assets justifies the acquisition.

Metric #3: Portfolio Additive And/Or Synergy

While most buyout situations are proposed to deliver pipeline synergy, the actual results tend to be value added (i.e., additive). In other words, creating synergy is extremely difficult. Therefore, a company typically gets additive value. From the figure below, you can appreciate that Pfizer is focused on rare diseases. Of those orphan conditions, Pfizer is dedicated to the innovation and commercialization of drugs to manage SCD.

Figure 5: Pfizer's focus on rare diseases

Rare disease focus

Pfizer

Given that GBT is a powerhouse innovator of therapeutics for SCD, there is at least value added (if not, synergy) with this union. Of the $27.7B in quarterly revenues that Pfizer procured in rare diseases, that account for the total of 3% of Pfizer's sales. As the company ramps up Oxbryta sales (as well as future launch for GBT601 and inclacumab), I believe that its rare disease portfolio would jump to at least 5% of total sales. Commenting on the M/A, the Chairman and CEO of Pfizer (Albert Bourla) enthused:

... We are excited to welcome GBT colleagues into Pfizer and to work together to transform the lives of patients, as we have long sought to address the needs of this underserved community (i.e., SCD). The deep market knowledge and scientific and clinical capabilities we have built over three decades in rare hematology will enable us to accelerate innovation for the sickle cell disease community and bring these treatments to patients as quickly as possible.

Figure 6: Pfizer's rare disease product sales

rare disease product sales

Pfizer

Notably, Oxbryta is already generating $195M for Fiscal 2021. By having access to Pfizer's powerful sales/marketing teams, GBT can now promptly send Oxbryta to many more patients afflicted by SCD. Consequently, you can expect Oxbryta revenue to hit around $500M annually in a year or two from now. Aside from Oxbryta's added value to Pfizer, you know that GBT601 (the oral, once-daily next-generation drug) is currently in a Phase 2/3 clinical study. On that front, the available data supports strong future clinical outcomes and thereby approval.

Additionally, GBT has the P-selectin inhibitor (i.e., inclacumab) that is being assessed in a Phase 3 study. Since both inclacumab and GBT601 are "orphan drugs," they command a premium reimbursement to reward the lengthy and costly innovation process. Ultimately, that would enhance the profit margin for Pfizer while delivering hopes to patients on a much larger scale.

Metric #4: Differentiating Characteristics

As you can appreciate, the aforementioned metrics are important for an acquisition. Nevertheless, the most crucial one is the differentiating characteristics of GBT's medicines. In a nutshell, there has to be something unique about the target's medicine to entice an acquisition. The more different the drug, the more attractive it is to the acquirer.

Interestingly, Oxbryta is the first and only of its kind (i.e., an oxygen binding affinity modulator), which differentiated it from competing drugs. The fact that it delivers stellar efficacy and safety while garnering robust year-over-year (YOY) sales is a strong indication of its blockbuster potential. Aside from Oxbryta, you know that GBT is also brewing two differentiated medicines: the next-generation drug (i.e., GBT601) and inclacumab. Putting all that together, it's a no-brainer for Pfizer to move forward with this deal.

Financial Assessment

Just as you would get an annual physical for your well-being, it's important to check up on the financial health of your stock. For instance, your health is affected by "blood flow" as your stock's viability is dependent on the "cash flow." With that in mind, I'll analyze the 2Q2022 earnings report for the period that concluded on June 30.

As follows, GBT procured $71.5M compared to $47.5M for the same period a year prior. On a YOY basis, the topline grew by the remarkable 50.5% clip. That aside, the research and development (R&D) for the respective registered at $64.7M and $51.7M. I viewed the 25.1% R&D increase positively because the capital invested today can generate blockbuster profits tomorrow. After all, you have to plant a tree to enjoy its fruits.

Additionally, there were $84.4M ($1.26 per share) net losses compared to $69.4 ($1.12 per share) net declines for the same comparison. On a per-share basis, the bottom line is improved by 12.5%. As Oxbryta sales continue to increase, the company would leverage the economy of scale to generate net profits.

Figure 7: Key financial metrics

key financials

GBT

About the balance sheet, there was $687.1M in cash and equivalents. On top of the $71.5M quarterly revenue (and against the $147.2M quarterly OpEx), there should be adequate capital to fund operations into 3Q2024 (i.e., 9 more quarters). Simply put, the cash position is quite robust.

Valuation Analysis

It's important that you appraise GBT to determine how much your shares are truly worth. Before running our figure, I liked to share with you the following:

Wall Street analysts typically employ a valuation method coined Discount Cash Flows (i.e., DCF). This valuation model follows a simple plug-and-chug approach. That aside, there are other valuation techniques such as price/sales and price/earnings. Now, there is no such thing as a right or wrong approach. The most important thing is to make sure you use the right technique for the appropriate type of stocks.

Given that developmental-stage biotech has yet to generate any revenues, I steer away from using DCF because it is most applicable for blue-chip equities. For developmental biotech, I leverage a combination of both qualitative and quantitative variables. That is to say, I take into account the quality of the drug, comparative market analysis, chances of clinical trial success, and potential market penetration. Qualitatively, I rely heavily on my intuition and forecasting experience over the years.

Figure 8: Valuation analysis

Molecules and franchises

Market potential and penetration

Net earnings based on a 25% margin

PT based on 64.4M shares outstanding and 10 P/E

"PT of the part" after appropriate discount

Oxbryta for SCD

$1.5B (estimated based on the $5.5B SCD market, growing at a 14.3% CAGR)

$375M $58.22 $52.39 (only 10% discount because it's gaining strong sales traction)
GBT601 for SCD $1B (estimated based on the $5.5B SCD market, growing at 14.3% CAGR) $250M $38.81 $19.40 (50% discount because it's still in early stage).

Inclacumab for SCD

$1B (estimated based on the $5.5B SCD market, growing at 14.3% CAGR) $250M $38.81 $19.40 (50% discount because it's still in early stage).
Younger pipeline assets Will appraise with more development in the future NA NA NA

The Sum of The Parts

$91.19

Potential Risks

Since investment research is an imperfect science, there are always risks associated with your stock regardless of its fundamental strengths. More importantly, the risks are "growth-cycle dependent." At this point in its life cycle, the most important concern for GBT is if the acquisition would be consummated. That aside, the risk for Pfizer is whether Oxbryta sales growth can be galvanized rapidly. The other risk is if the other pipeline assets (i.e., GBT601 and inclacumab) would generate positive data.

Conclusion

In all, I maintain my buy recommendation on Global Blood Therapeutics with the 5/5 stars (i.e., raised from 4.8) rating. Global Blood Therapeutics is a story of investment success. As a stellar medicine, Oxbryta triumphed against market doubts and thereby gained approval to deliver hopes to patients afflicted by SCD. In early commercialization, Oxbryta demonstrated that it can deliver strong sales traction at the 41% YOY growth rate. As the Pfizer acquisition is consummated, you can expect that Oxbryta sales to quickly ramp up due to the robust sales/marketing of Pfizer. Looking ahead, GBT601 and inclacumab would deliver strong data and thus gain approval. After this deal, you can expect more M/A activities to pick up for the remainder of the year.

Thanks for reading! To read the full article, CLICK HERE. To get the latest articles, please hit the orange “Follow” button on top.

Be sure to check out our private investment research community, Integrated BioSci Investing.

Dr. Tran's analyses are the best in the biotech sphere, well worth the price of subscription.

Very professional, extremely knowledgeable and very honest … I would highly recommend this service and his stock picks have been very profitable.

Simply put, this is worth every penny. Just earlier today, one of the companies recommended by Dr. Tran got acquired for a nice 50% premium.

Click here for a FREE TRIAL.

This article was written by

BioSci Capital Partners profile picture
15.31K Followers
Become an Expert Bio-Investor with the Columbia Doc/Scientist/Market Whiz

Founded by Dr. Harvey Tran MD, MS, CNPR, (in collaboration with other PhDs), Integrated BioSci Investing LLC (“IBI) is a growing community of experts and everyday investors who help one another to invest better.

We bring to you a NEW investment philosophy called “Integrated BioSci Investing.” It's a distillation of value/growth investing wisdom from gurus such as Warren Buffett, Buffet's mentors (Ben Graham and Phil Fischer), and Sir John Templeton that are adapted specifically for biotech stocks.

IBI's analytical research is powered by the integration of (medical, scientific, and market) expertise to deliver unprecedented accuracy in clinical trial forecasting that, in and of itself, is one of the requisites to finding alpha bioscience investment.

Ultimately, our tireless due diligence and the wisdom of IBI members translate into strong returns for you. To name a couple of winners, Crispr Therapeutics (CRSP), CryoPort (CYRX), and Guardant Health (GH), correspondingly delivered 679.1%, 778.3%, and +435.9% for our subscribers."

As an IBI member, you’ll enjoy the following EXCLUSIVE benefits: daily real-time research articles that are comprehensive and more in-depth than free research articles; access to the chat room with many experts and everyday investors for you to ask your questions live about your favorite stocks (you’re expected to get an answer no later than 24 hours); ability to view our high performing portfolios and their pertinent updates; consulting on strategies to help you set up your own portfolios; Our best ideas and their updates via a research article or chat; potential to have research featured on your favorite companies; ability to reach Dr. Tran via phone call or Skype as you wish.

CLICK the orange FOLLOW button to receive the FREE real-time alerts on our articles and blogs.

CONNECT with Dr. Tran through his LinkedTree https://linktr.ee/DrHarveyTran

READ more on www.drtranbiosci.com (and make sure to register for our mailing list).

LEARN about Dr. Tran’s background in an in-depth article by following this link. http://www.drtranbiosci.com/p/dr-tran.html

"Stellar therapeutics for patients. Differentiated intelligence for investors. Premium valuations for firms."

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: As a medical doctor/market expert, I'm not a registered investment advisor. Despite that I strive to provide the most accurate information, I neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. I reserve the right to make any investment decision for myself and my affiliates pertaining to any security without notification except where it is required by law. I'm also NOT responsible for the action of my affiliates. The thesis that I presented may change anytime due to the changing nature of information itself. Investing in stocks and options can result in a loss of capital. The information presented should NOT be construed as recommendations to buy or sell any form of security. My articles are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your action. You should also consult with your own financial advisor for specific guidance, as financial circumstances are individualized. That aside, I'm not giving you professional medical advice. Before embarking on any health-changing behavior, make sure you consult with your own doctor.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.